The pharmaceutical industry in 2026 has reached a regulatory tipping point where bioprinted "Human-on-a-Chip" models are now preferred over traditional animal testing for Phase 1 toxicity trials. Under new global harmonization agreements, drug manufacturers are using bioprinted liver, kidney, and heart tissues to predict human metabolism with over 90% accuracy. This transition is not only...
English
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek